<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02115776</url>
  </required_header>
  <id_info>
    <org_study_id>PGIDIT05PXIB92501PR</org_study_id>
    <nct_id>NCT02115776</nct_id>
  </id_info>
  <brief_title>A New Antibiotic Prophylaxis Regimen to Prevent Bacteremia Following Dental Procedures</brief_title>
  <official_title>A New Antibiotic Prophylaxis Regimen to Prevent Bacteremia Following Dental Procedures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Santiago de Compostela</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Clinico Universitario de Santiago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Santiago de Compostela</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate the efficacy of prophylactic dosage with amoxicillin
      (AMX), amoxicillin-clavulanate (AMX-CLV), and a combination of amoxicillin-clavulanate and a
      chlorhexidine mouthwash (AMX-CLV-CHX) in the prevention of bacteremia following dental
      extractions.

      The study hypothesis is that an antimicrobial regimen with amoxicillin-clavulanate will show
      higher effectiveness in reducing the prevalence and duration of bacteremia following dental
      extractions, than that achieved with the classical amoxicillin regimen.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PURPOSE: Despite the controversy about the risk of developing bacterial endocarditis of oral
      origin, numerous Expert Committees in different countries continue to publish prophylactic
      regimens. To date, the literature is unclear about the role of antimicrobial prophylaxis in
      the prevention of bacteremia following dental procedures. The aim of this study is to
      evaluate the efficacy of prophylactic dosage with amoxicillin (AMX), amoxicillin-clavulanate
      (AMX-CLV), and a combination of amoxicillin-clavulanate and a CHX mouthwash (AMX-CLV-CHX) in
      the prevention of bacteremia following dental extractions.

      SELECTION OF THE STUDY GROUP AND STUDY DESIGN: The study group will comprise patients who,
      for behavioral reasons (autism, learning disabilities, phobias, etc.), will undergo dental
      extractions under general anesthesia in the Santiago de Compostela University Hospital
      (Santiago de Compostela, Spain). The following exclusion criteria will be applied: age under
      18 years; body weight under 40 kg; receipt of antibiotics in the previous 3 months; routine
      use of oral antiseptics; a history of allergy or intolerance to AMX, CHX or AMX-CLV; any type
      of congenital or acquired immunodeficiency; or any known risk factor for bacterial
      endocarditis. By applying these criteria, 200 patients will be selected and will be randomly
      distributed into 5 study groups: control group (receiving no prophylaxis), AMX group
      (receiving 2 g AMX i.v.), AMX-CLV group (receiving 1000/200mg AMX-CLV i.v.), CHX group
      (receiving a single 0.2% CHX mouthwash for 30 seconds), and AMX-CLV-CHX group (receiving
      1000/200mg AMX-CLV i.v. and a single 0.2% CHX mouthwash for 30 seconds).

      COLLECTION OF SAMPLES FOR BLOOD CULTURE: To determine the prevalence of bacteremia, a
      peripheral venous blood sample (10 ml) will be drawn from each patient at the baseline
      (before any dental manipulation but after nasotracheal intubation) and 30 s, 15 min, and 1 h
      after the final dental extraction. Samples will be inoculated in BACTEC plus (Becton
      Dickinson and Company, Sparks, MD) aerobic and anaerobic blood culture bottles, and will be
      processed in the Bactec 9240 (Becton Dickinson).

      MICROBIOLOGICAL ANALYSIS OF BLOOD CULTURES: A Gram stain will be performed on each positive
      blood culture. The positive blood cultures in the aerobic media will be subcultured on blood
      agar and chocolate agar in an atmosphere of 5 to 10% carbon monoxide and on MacConkey agar
      under aerobic conditions. The same protocol will be used for the positive blood cultures in
      the anaerobic media, with subculture on Schaedler agar and incubation in an anaerobic
      atmosphere. The bacteria isolated will be identified by using the battery of biochemical
      tests provided with the Vitek system for Gram-positive bacteria, Neisseria spp., Haemophilus
      spp., and obligate anaerobic bacteria. The viridans group streptococci will be classified
      into five groups, the Streptococcus mitis, S. anginosus, S. salivarius, S. mutans, and S.
      bovis groups, by applying the Ruoff criteria. Facklam's criteria will be used to identify
      unusual Streptococcus spp. and other gram-positive cocci in chains.

      The subculture and further identification of the isolated bacteria will be performed by
      conventional microbiological techniques. The collection, handling, and transport of the blood
      samples for blood culture will be performed according to the recommendations of the Spanish
      Society of Infectious Diseases and Clinical Microbiology.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">May 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants receiving a prophylactic dosage with amoxicillin-clavulanate i.v. with bacteremia following dental extractions</measure>
    <time_frame>Changes from baseline in prevalence of bacteremia at 30 seconds, 15 minutes and 1 hour after the final dental extraction</time_frame>
    <description>Percentage of participants receiving a prophylactic dosage with amoxicillin-clavulanate i.v. with bacteremia confirmed by microbiological analysis at 30 seconds, 15 minutes and 1 hour after the final dental extraction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants receiving a prophylactic dosage with amoxicillin i.v. (following the American Heart Association´s guidelines) with bacteremia after dental extractions</measure>
    <time_frame>Changes from baseline in prevalence of bacteremia at 30 seconds, 15 minutes and 1 hour after the final dental extraction</time_frame>
    <description>Percentage of participants receiving a prophylactic dosage with amoxicillin i.v. with bacteremia confirmed by microbiological analysis at 30 seconds, 15 minutes and 1 hour after the final dental extraction</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of control participants with bacteremia following dental extractions under general anesthesia</measure>
    <time_frame>Changes from baseline in prevalence of bacteremia at 30 seconds, 15 minutes and 1 hour after the final dental extraction</time_frame>
    <description>Percentage of control participants with bacteremia confirmed by microbiological analysis at 30 seconds, 15 minutes and 1 hour after the final dental extraction</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">266</enrollment>
  <condition>Bacteremia</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Receiving no prophylaxis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amoxicillin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receiving 2 g Amoxicillin intravenously before any dental manipulation and following endotracheal intubation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amoxicillin-Potassium Clavulanate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving 1000/200mg Amoxicillin-Potassium Clavulanate i.v. before any dental manipulation and following endotracheal intubation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chlorhexidine (CHX)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Receiving a single 0.2% Chlorhexidine (CHX) mouthwash for 30 seconds before any dental manipulation and following endotracheal intubation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amoxicillin-Potassium Clavulanate-CHX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Receiving 1000/200mg Amoxicillin-Potassium Clavulanate i.v. and a single 0.2% Chlorhexidine (CHX) mouthwash for 30 seconds before any dental manipulation and following endotracheal intubation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin-Potassium Clavulanate</intervention_name>
    <description>Administer Amoxicillin-Potassium Clavulanate following endotracheal intubation prior to single tooth-extraction</description>
    <arm_group_label>Amoxicillin-Potassium Clavulanate</arm_group_label>
    <arm_group_label>Amoxicillin-Potassium Clavulanate-CHX</arm_group_label>
    <other_name>AMOXICILINA + ACIDO CLAVULANICO SANDOZ EFG (code 600144)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Administer Amoxicillin following endotracheal intubation prior to single tooth-extraction</description>
    <arm_group_label>Amoxicillin</arm_group_label>
    <other_name>AMOXICILINA SANDOZ EFG (code 694688)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chlorhexidine</intervention_name>
    <description>Administer Chlorhexidine Digluconate following endotracheal intubation prior to single tooth extraction</description>
    <arm_group_label>Chlorhexidine (CHX)</arm_group_label>
    <arm_group_label>Amoxicillin-Potassium Clavulanate-CHX</arm_group_label>
    <other_name>Oraldine Perio (code 375725)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must have at least 10 teeth

          -  Subjects must have the need for a dental extraction under general anesthesia (for
             behavioral reasons)

          -  Subjects will be recruited regardless of the extent and severity of their dental
             and/or periodontal disease

        Exclusion Criteria:

          -  Age under 18 years

          -  Body weight under 40 kg

          -  Receipt of antibiotics in the previous 3 months

          -  Routine use of oral antiseptics

          -  A history of allergy or intolerance to amoxicillin

          -  A history of allergy or intolerance to chlorhexidine

          -  A history of allergy or intolerance to amoxicillin-clavulanate

          -  Any type of congenital or acquired immunodeficiency

          -  Any known risk factor for bacterial endocarditis

          -  Any known risk factor for prolonged bleeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Diz, MD,DDS,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Universidad de Santiago (Grupo OMEQUI-2117); Hospital Clínico Universitario de Santiago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jacobo Limeres, DDS,PhD</last_name>
    <role>Study Director</role>
    <affiliation>Universidad de Santiago (Grupo OMEQUI-2117)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier Alvarez, MD,DDS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Santiago (Grupo OMEQUI-2117)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Javier F Feijoo, MD,DDS,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Santiago (Grupo OMEQUI-2117); Hospital Clínico Universitario de Santiago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcio Diniz, DDS,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Santiago (Grupo OMEQUI-2117)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mercedes Outumuro, DDS,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Santiago (Grupo OMEQUI-2117)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan Medina, MD,Anest,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario de Santiago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel Castro, MD,DDS, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidad de Santiago (Grupo OMEQUI-2117)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Maximiliano Alvarez, MD,Micro,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínico Universitario de Vigo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>A Coruña</state>
        <zip>15782</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santiago de Compostela University Hospital</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Coruña</state>
        <zip>15782</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Tomás I, Alvarez M, Limeres J, Potel C, Medina J, Diz P. Prevalence, duration and aetiology of bacteraemia following dental extractions. Oral Dis. 2007 Jan;13(1):56-62.</citation>
    <PMID>17241431</PMID>
  </reference>
  <reference>
    <citation>Tomás I, Pereira F, Llucián R, Poveda R, Diz P, Bagán JV. Prevalence of bacteraemia following third molar surgery. Oral Dis. 2008 Jan;14(1):89-94. doi: 10.1111/j.1601-0825.2006.01359.x.</citation>
    <PMID>18173454</PMID>
  </reference>
  <reference>
    <citation>Valdés C, Tomás I, Alvarez M, Limeres J, Medina J, Diz P. The incidence of bacteraemia associated with tracheal intubation. Anaesthesia. 2008 Jun;63(6):588-92. doi: 10.1111/j.1365-2044.2008.05449.x.</citation>
    <PMID>18477269</PMID>
  </reference>
  <reference>
    <citation>Piñeiro A, Tomás I, Blanco J, Alvarez M, Seoane J, Diz P. Bacteraemia following dental implants' placement. Clin Oral Implants Res. 2010 Sep;21(9):913-8. doi: 10.1111/j.1600-0501.2010.01928.x.</citation>
    <PMID>20701619</PMID>
  </reference>
  <reference>
    <citation>Tomás I, Diz P, Tobías A, Scully C, Donos N. Periodontal health status and bacteraemia from daily oral activities: systematic review/meta-analysis. J Clin Periodontol. 2012 Mar;39(3):213-28. doi: 10.1111/j.1600-051X.2011.01784.x. Epub 2011 Sep 15. Review.</citation>
    <PMID>22092606</PMID>
  </reference>
  <reference>
    <citation>Diz Dios P, Tomás Carmona I, Limeres Posse J, Medina Henríquez J, Fernández Feijoo J, Alvarez Fernández M. Comparative efficacies of amoxicillin, clindamycin, and moxifloxacin in prevention of bacteremia following dental extractions. Antimicrob Agents Chemother. 2006 Sep;50(9):2996-3002.</citation>
    <PMID>16940094</PMID>
  </reference>
  <reference>
    <citation>Diz Dios P. Infective endocarditis prophylaxis. Oral Dis. 2014 May;20(4):325-8. doi: 10.1111/odi.12221. Epub 2014 Jan 13. Review.</citation>
    <PMID>24373017</PMID>
  </reference>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2014</study_first_posted>
  <last_update_submitted>May 26, 2015</last_update_submitted>
  <last_update_submitted_qc>May 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Santiago de Compostela</investigator_affiliation>
    <investigator_full_name>Pedro DIz DIos</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>bacteremia</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>antibiotics</keyword>
  <keyword>dentistry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Clavulanic Acid</mesh_term>
    <mesh_term>Clavulanic Acids</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
    <mesh_term>Chlorhexidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

